Your session is about to expire
← Back to Search
Virus Therapy
AlloStim for Coronavirus Disease (ALLOPRIME Trial)
Phase 1 & 2
Waitlist Available
Research Sponsored by Mirror Biologics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 0 to day 28
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a special vaccine made from healthy blood cells to help elderly adults fight off any virus. The vaccine boosts the immune system by creating memory cells that quickly recognize and combat viruses.
Eligible Conditions
- Coronavirus Disease (COVID-19)
- Central Nervous System Viral Infection
- Flu-Related Pain
- Pneumonia
- Respiratory Syncytial Virus Pneumonia
- Viral Diseases
- Flu
- Acute respiratory distress syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 0 to day 28
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 0 to day 28
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Proportion of subjects able to suppress viral propagation
Proportion of subjects with positive T-cell response
frequency of vaccine events
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: VaccinationExperimental Treatment1 Intervention
ID injection AlloStim Days 0, 3/4, 7, 10/11 and 14
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AlloStim
2016
Completed Phase 2
~90
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Mirror Biologics, Inc.Lead Sponsor
14 Previous Clinical Trials
321 Total Patients Enrolled
Immunovative Therapies, Ltd.Lead Sponsor
13 Previous Clinical Trials
271 Total Patients Enrolled
David Fineberg, MDStudy DirectorMirror Biologics, Inc.
2 Previous Clinical Trials
Share this study with friends
Copy Link
Messenger